Vnitr Lek 2019, 65(12):809-814 | DOI: 10.36290/vnl.2019.140

Importance of fixed-dose combinations in cardiovascular prevention: the possibility of treating two diagnoses with a single pill

Eva Tůmová, Michal Vrablík^*

Centrum preventivní kardiologie, III. interní klinika - klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze

In the care of a cardiovascular risk patient there is certainly a more frequent situation in which we try to influence several risk factors at the same time. Treatment of a single self-occurring risk factor is rather an exception. In most cases, we need to intervene with more risk factors, often involving combination therapy, which can achieve the desired goals more quickly and reliably. However, with the number of tablets taken by the patient, the patient's willingness to take long-term and correct use decreases, which has a significant impact on the effectiveness of therapy and the development of individual cardiovascular risk. In an effort to control all risk factors for cardiovascular disease, there is a growing need to extend the availability of fixed drug formulations to suit the patient's ease of use and suitably formulated with varying dose grades to meet the needs of our attending physicians. With regard to the fact that early intervention of risk factors brings greater benefits than deferred, we are looking for appropriate ways to manage it. The current intervention of arterial hypertension and dyslipidemia with safe and proven drugs seems to be one of the ways to further improve the results of the prevention of cardiovascular diseases. The new fixed combination of atorvastatin with perindopril, which is entering the Czech market right now, appears to be in many ways an ideal "tablet for cardiovascular prevention".

Keywords: cardiovascular risk; dyslipidemia; hypertension; prevention; single pill combination; synergy

Received: November 19, 2019; Accepted: November 27, 2019; Published: December 1, 2019  Show citation